Aktie A2N7LU PHASEBIO PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen PhaseBio Pharmaceuticals, Inc.

Aktien

A2N7LU

US7172241090

PHAS.Q

Schlusskurs OTC Markets
Andere Börsenplätze
 00:00:00 16.04.2024 		% 5 Tage % 1. Jan.
0.000001 USD 0.00% Intraday Chart für PhaseBio Pharmaceuticals, Inc. 0.00% 0.00%
07.02. Fünfter Antrag auf Verlängerung der Exklusivitätsfrist für PhaseBio Pharmaceuticals, Inc. bewilligt CI
2023 Vierter Antrag auf Verlängerung der Exklusivitätsfrist für PhaseBio Pharmaceuticals, Inc. bewilligt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
First Amended Combined Liquidation Plan and Disclousre Statement Filed by PhaseBio Pharmaceuticals, Inc.
Fifth Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.
Fourth Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc. Announces Resignation of Caroline Loewy as Member of the Board of Directors
Third Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.
Modified Combined Disclosure Statement Approved on Interim Basis for PhaseBio Pharmaceuticals, Inc.
Second Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.
Combined Liquidation Plan and Disclousre Statement Filed by PhaseBio Pharmaceuticals, Inc.
North American Morning Briefing : Sentiment -2-
North American Morning Briefing : Traders Await -2-
North American Morning Briefing : Stock Futures -3-
First Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.
First Motion for Exclusivity Period Extension Filed by PhaseBio Pharmaceuticals, Inc.
Motion for Asset Sale Approved for PhaseBio Pharmaceuticals, Inc.
Motion for Asset Sale Approved for PhaseBio Pharmaceuticals, Inc.
Motion for De Minimis Assets Sale Approved for PhaseBio Pharmaceuticals, Inc.
Notice of Selection of Auction and Asset Purchase Agreement Filed for Filed by PhaseBio Pharmaceuticals, Inc.
Chiesi Farmaceutici S.p.A. cancelled the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab.
Notice of Rescheduled Auction Filed by PhaseBio Pharmaceuticals, Inc.
Motion for Asset Sale Approved for PhaseBio Pharmaceuticals, Inc.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2N7LU Aktie
  4. Nachrichten PhaseBio Pharmaceuticals, Inc.
  5. Andere Sprachen